Novo Nordisk
426,55
DKK
-1,81 %
Mindre end 1K følgere
NOVO B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-1,81%
+0,21%
-23,49%
-31,66%
-40,01%
-53,49%
+13,88%
+94,11%
+34.161,04%
Novo Nordisk er producent af insulin til behandling af diabetes. Ud over specialkundskaben inden for diabetes producerer virksomheden lægemidler til hormonbehandling, samt produkter til hæmofili og blødningsforstyrrelser. Produkterne findes på det globale marked og sælges under separate mærker. Virksomheden blev oprindeligt grundlagt i 1923 og har hovedsæde i Bagsværd.
Læs mereMarkedsværdi
1,9 bio. DKK
Aktieomsætning
4,46 mia. DKK
Omsætning
290,4 mia.
EBIT %
44,19 %
P/E
18,82
Udbytteafkast, %
2,67 %
Finanskalender
6.8
2025
Delårsrapport Q2'25
5.11
2025
Delårsrapport Q3'25
Alle
Analyse
Selskabsmeddelelser
ViserAlle indholdstyper
Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk
Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025
Novo Nordisk announces changes in Executive Management
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025
Resolutions from the Annual General Meeting of Novo Nordisk A/S
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S
